Everest Organics Limited

EVERESTO6

INE334C01029

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:56 01/07/2024 pm IST			5-day change	1st Jan Change
138.1 ^INR	+0.25%		+1.43%	+9.04%

07/06	Everest Organics Limited Announces Resignation of Abdur Rahman as Company Secretary & Compliance Officer	CI
27/05	Everest Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Everest Organics Limited Recommends Dividend for the Financial Year 2021-22

May 27, 2022 at 05:01 pm IST

Everest Organics Limited at the board meeting held on May 27, 2022, recommended dividend of INR 0.50 paisa per equity shares of the face value of INR 10 each for the financial year 2021-22, subject to the approval of the Members at the ensuing Annual General Meeting.

Latest news about Everest Organics Limited

Everest Organics Limited Announces Resignation of Abdur Rahman as Company Secretary & Compliance Officer	07/06	CI
Everest Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	27/05	CI
Everest Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	09/02	CI
Everest Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	09/02	CI
Everest Organics Limited Appoints Abdur Rahman as Company Secretary and Compliance Officer	11/11	CI
Everest Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11/11	CI
Everest Organics Limited Announces Resignation of Rekha Singh as Company Secretary and Compliance Officer	09/23/09	CI
Everest Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	12/23/12	CI
Everest Organics Limited Announces the Demise of Sree Rama Krishna Grandhi, Non-Executive Independent Director	01/23/01	CI
Everest Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	27/23/27	CI
Everest Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
Everest Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	11/22/11	CI
Everest Organics Limited Declares Dividend for the Financial Year Ended March 31, 2022	26/22/26	CI
ICRA Cuts Rating on Everest Organics' Term Loan, Cash Credit to B+; Raises Outlook to Stabe	23/22/23	MT
Everest Organics Names New Managing Director; Shares Climb 3%	09/22/09	MT
Everest Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	09/22/09	CI
ICRA Cuts Rating on Everest Organics' Term Loan, Cash Credit to BB; Outlook Lowered to Negative	09/22/09	MT
Everest Organics Limited Announces the Demise of Dr. Srikakarlapudi Srihari Raju, Managing Director	27/22/27	CI
Everest Organics Limited Recommends Dividend for the Financial Year 2021-22	27/22/27	CI
Everest Organics Managing Director Passes Away	27/22/27	MT
Everest Organics Limited Announces Demise of Dr. Srikakarlapudi Srihari Raju, Managing Director of the Company	27/22/27	CI
ICRA Cuts Rating on Everest Organics' Term Loan, Cash Credit to BB+; Outlook Stable	03/22/03	MT
Everest Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	11/22/11	CI
Everest Organics Gets Permanent Revocation of Factory Closure Order	10/22/10	MT
Everest Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	13/21/13	CI

Chart Everest Organics Limited

Duration

Period

More charts

Company Profile

Everest Organics Limited is engaged in manufacturing of active pharmaceutical ingredients (API) and their intermediaries. It is involved in manufacturing of bulk drugs, such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen, Benzimadizole. The Companyâs APIâs products include Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Tamsulosin Hcl, and Dexlansoprazole. Its products under development include Remdesivir, Molnupiravir, Carbidopa, Acotiamide HCL, and Apixaban. Its intermediates products include Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5- Thiazolecarboxylate, Ethyl 2-(3-Formyl -4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Formyl -4-Isobutoxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Cyano -4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate, and 2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride.

Sector

Pharmaceuticals

Calendar

01/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
EVEREST ORGANICS LIMITED	+9.04%	13.22M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.70%	43.77B
OTSUKA HOLDINGS CO., LTD.	+30.16%	22.83B
SANDOZ GROUP AG	+20.25%	15.56B
CIPLA LIMITED	+18.68%	14.34B
ZYDUS LIFESCIENCES LIMITED	+54.86%	12.96B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.72%	6.41B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.65%	5.69B